西布曲明对比奥利司他治疗肥胖症的Meta分析

目的：系统评价西布曲明与奥利司他治疗肥胖症的临床疗效及其临床应用价值。方法：计算机检索PubMed、EMBASE、SCI、CochraneLi-brary、中国生物医学文献数据库、中文科技期刊全文数据库、中国期刊全文数据库及中华医学会数字化期刊,收集西布曲明与奥利司他治疗肥胖症的随机对照试验,检索时间截至2009年12月。采用Cochrane系统评价员手册文献质量评价标准评价纳入研究质量,用RevMan5.0软件进行Meta分析。结果：共纳入5个随机对照试验,研究地点均在国外。Meta分析结果显示：在体重减轻、体重指数（BMI）降低、腰围减少、低密度脂蛋白降低的比较上,西布曲明组与奥利司他组均有明显的减肥效果,但两药减肥效果无差异。两组间不良反应较少,但由于药物作用机制不同,不良反应的表现不同。结论：西布曲明与奥利司他在治疗肥胖上有显著疗效,两者间无明显差异,同时两组药物间不良反应表现不同。

Sibutramine versus orlistat for obesity: A Meta-analysis of randomized controlled trials

AIM：To compare the efficacy and investigate the clinic value between sibutramine and orlistat for obesity.METHODS：The database was retrieved from PubMed,EMBASE,SCI,the Cochrane Library,Chinese Biomedical Literature Database,China Journal Full TextDatabase,Chinese Medical Association Journals,and references of the included studies up to December 2009.Randomized control trials （RCT） of sibutramine versus orlistat for obesity were included.The quality of the included studies was evaluated by Handbook recommend standard.Data were analyzed by RevMan 5.0 from the Cochrane Collaboration.RESULTS：Five RCTs were included.Meta-analysis showed that there were no differences between sibutramine and orlistat for obesity in weight loss,body mass index（BMI） decrease,waist circumference decrease and LDL-C change.Although there were fewer adverse events in the two groups,the form of adverse events were different because of the different mechanism of two drugs.CONCLUSION：Sibutramine and Orlistat have significant effects in the treatment of obesity.Meanwhile,there is no significant difference between two drugs,while the performance of two groups of drug adverse events is different.